Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Molecular markers predict treatment response in lymphoma better than current staging systems, enabling doctors to tailor therapy intensity based on individual tumor biology.
This large Italian FIL consortium analysis of the prospective V-RBAC MCL trial demonstrates that molecular biomarkers — including SOX11, TP53, MYC, and cell-of-origin classification — are key independent determinants of response and survival in mantle cell lymphoma. The findings provide a molecular framework for risk-adaptive treatment selection in this heterogeneous and often incurable B-cell malignancy.
What the study was
- Study design
- Prospective multicenter clinical trial analysis (Italian FIL V-RBAC trial cohort)
- Population
- Patients with mantle cell lymphoma enrolled in the FIL V-RBAC prospective trial
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Blood advances
Why it surfaced
Large Italian FIL consortium analysis from prospective V-RBAC MCL trial confirming molecular biomarkers as key outcome predictors. Supports biomarker-driven treatment algorithms for MCL. Gaidano/Visco group; Blood Advances.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.